← Back to Search

Multicomponent intervention for Kidney Disease (EnAKT LKD Trial)

N/A
Waitlist Available
Led By Amit Garg, MD, PhD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4.17 years
Awards & highlights

EnAKT LKD Trial Summary

This trial will help determine if a multi-component quality improvement intervention can enable more patients with no recorded contraindications to kidney transplant to complete more steps towards receiving a kidney transplant.

Eligible Conditions
  • Kidney Disease
  • Kidney Failure

EnAKT LKD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4.17 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4.17 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Completing key steps toward receiving a kidney transplant
Secondary outcome measures
A patient receives a living donor kidney transplant
A patient receives a pre-emptive living donor kidney transplant (restricted to patients who were not receiving dialysis when they entered the trial and not on dialysis at the time of transplant).
A potential living kidney donor begins their evaluation at a transplant center to donate a kidney to the patient and/or a patient receives a living donor transplant.
+2 more
Other outcome measures
Average number of months from the date of dialysis initiation (i.e. trial entry) to the date of referral
Average number of months from the date of referral to a transplant center to date of the transplant surgery
Average number of months from the date of referral to a transplant center to the date the first living donor candidate contacts the transplant centre for the intended recipient
+3 more

EnAKT LKD Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Multicomponent interventionExperimental Treatment1 Intervention
A multicomponent intervention will be provided at chronic kidney disease (CKD) programs.
Group II: Usual CareActive Control1 Intervention
CKD programs will continue to support access to kidney transplantation and living kidney donation as they usually do for CKD patients.

Find a Location

Who is running the clinical trial?

Institute for Clinical Evaluative SciencesOTHER
36 Previous Clinical Trials
2,509,073 Total Patients Enrolled
Lawson Health Research InstituteLead Sponsor
656 Previous Clinical Trials
413,402 Total Patients Enrolled
Institute for Clinical Evaluative Sciences (ICES)UNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Enhance Access to Kidney Transplantation and Living Kidney Donation
2017. "Enhance Access to Kidney Transplantation and Living Kidney Donation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03329521.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top